This page identifies medical, scientific, and regulatory resources relevant to the educational information presented on this website about Alecnib 150 mg and alectinib.
Alecnib is identified on this website as a product containing alectinib in a stated strength of 150 mg. Alectinib is a targeted anticancer medicine classified as an anaplastic lymphoma kinase (ALK) inhibitor. It is used for certain patients with ALK-positive non-small cell lung cancer (NSCLC).
The information published across this website covers the medicine’s therapeutic uses, mechanism of action, dosage principles, administration, safety information, potential adverse reactions, and clinical research.
The references below provide background information about alectinib. They do not independently establish the manufacturer, authenticity, regulatory authorization, or pharmaceutical quality of Alecnib.
1. Official Regulatory and Prescribing Information
Official medicine documentation is an important source for understanding approved indications, dosage recommendations, contraindications, warnings, precautions, and adverse reactions.
Reference 1: United States Prescribing Information for Alecensa
- Document: Alecensa (alectinib) Capsules — Full Prescribing Information.
- Regulatory authority: United States Food and Drug Administration (FDA).
- Product associated with document: Alecensa.
- Active ingredient: Alectinib.
- Initial United States approval: 2015.
- Document version consulted: August 2026 revision.
Relevant information:
- Approved therapeutic indications.
- Adult dosage and administration.
- Dosage modifications.
- Contraindications.
- Liver-related warnings.
- Lung inflammation and pneumonitis.
- Bradycardia.
- Muscle-related adverse reactions.
- Hemolytic anemia.
- Kidney impairment.
- Hypertriglyceridemia and pancreatitis.
- Embryo-fetal toxicity.
- Drug interactions and monitoring.
This document is a reference for the established Alecensa product. It is not an official prescribing document for Alecnib.
Reference 2: European Medicines Agency — Alecensa
- Organization: European Medicines Agency (EMA).
- Document: Alecensa European Public Assessment Report (EPAR).
- Active ingredient: Alectinib.
- Therapeutic area: Non-small cell lung cancer.
- European Union marketing authorization: 16 February 2017.
- Reference document information: EMA medicine overview and product information.
Relevant information:
- European regulatory assessment.
- Approved therapeutic indications.
- ALK-positive NSCLC treatment.
- Administration and dosage.
- Clinical benefit and safety.
- Product information and patient precautions.
Reference 3: European Product Information for Alecensa
- Organization: European Medicines Agency.
- Document: Alecensa 150 mg Hard Capsules — Summary of Product Characteristics and Package Leaflet.
- Active ingredient: Alectinib hydrochloride.
- Dosage form: Hard capsules.
- Strength: 150 mg alectinib per capsule.
Relevant information:
- Pharmaceutical composition.
- Dosage form and administration.
- Therapeutic indications.
- Clinical precautions.
- Adverse reactions.
- Special patient populations.
- Pregnancy and breastfeeding information.
The European product information applies to Alecensa and should not automatically be treated as the approved product information for Alecnib.
2. Major Clinical Trials of Alectinib
Clinical trials provide evidence about the effectiveness and safety of alectinib in defined patient populations.
Reference 4: ALEX Clinical Trial
Article title: Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer.
- Lead author: Solange Peters and colleagues.
- Journal: The New England Journal of Medicine.
- Publication year: 2017.
- Volume: 377.
- Issue: 9.
- Pages: 829–838.
- DOI: 10.1056/NEJMoa1704795.
- Clinical trial: ALEX.
Research focus:
The ALEX study compared alectinib with crizotinib in previously untreated patients with advanced ALK-positive NSCLC.
The study evaluated treatment effectiveness, progression-free survival, central nervous system activity, and safety.
Relevance to this website:
This study provides important clinical evidence supporting alectinib as a targeted treatment for advanced ALK-positive NSCLC.
Reference 5: ALEX Final Overall Survival Analysis
Article title: Alectinib versus Crizotinib in Previously Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer: Final Overall Survival Analysis of the Phase III ALEX Study.
- Journal: Annals of Oncology.
- Publication year: 2026.
- Volume: 37.
- Issue: 1.
- Pages: 92–103.
- DOI: 10.1016/j.annonc.2025.09.018.
Research focus:
This publication reports mature overall survival, duration of response, and long-term safety findings from the ALEX study.
Relevance to this website:
It provides additional information about long-term treatment outcomes and safety in patients receiving alectinib for advanced ALK-positive NSCLC.
Reference 6: ALINA Clinical Trial
Article title: Alectinib in Resected ALK-Positive Non–Small-Cell Lung Cancer.
- Lead author: Yi-Long Wu and colleagues.
- Journal: The New England Journal of Medicine.
- Publication year: 2024.
- Volume: 390.
- Issue: 14.
- Pages: 1265–1276.
- DOI: 10.1056/NEJMoa2310532.
- Clinical trial: ALINA.
- Trial registration: NCT03456076.
Research focus:
The ALINA study evaluated adjuvant alectinib against platinum-based chemotherapy in patients with completely resected ALK-positive NSCLC.
The study assessed disease-free survival, central nervous system disease-free survival, overall survival, and safety.
Relevance to this website:
This research supports the clinical role of alectinib as postoperative adjuvant treatment in eligible patients with resected ALK-positive NSCLC.
Reference 7: ALINA Safety and Quality-of-Life Analysis
Article title: Adjuvant Alectinib versus Chemotherapy in Resected ALK-Positive Non-Small-Cell Lung Cancer (ALINA): Health-Related Quality-of-Life and Safety Outcomes from a Randomised, Open-Label, Phase 3 Trial.
- Journal: The Lancet Oncology.
- Publication year: 2026.
- Volume: 27.
- Issue: 9.
- Pages: 1110–1119.
- DOI: 10.1016/S1470-2045(26)00283-4.
- Clinical trial: ALINA.
Research focus:
This publication examines the safety profile and health-related quality-of-life outcomes associated with adjuvant alectinib compared with chemotherapy.
Relevance to this website:
It provides additional information about treatment tolerability and patient-reported health outcomes during postoperative alectinib treatment.
Reference 8: J-ALEX Clinical Trial
Article title: Alectinib versus Crizotinib in Patients with ALK-Positive Non-Small-Cell Lung Cancer (J-ALEX): An Open-Label, Randomised Phase 3 Trial.
- Journal: The Lancet.
- Publication year: 2017.
- Volume: 390.
- Issue: 10089.
- Pages: 29–39.
- DOI: 10.1016/S0140-6736(17)30565-2.
- Clinical trial: J-ALEX.
Research focus:
The J-ALEX study compared alectinib with crizotinib in patients with ALK-positive NSCLC in a Japanese clinical trial population.
Relevance to this website:
The study contributes to the clinical evidence supporting ALK inhibition with alectinib.
3. Molecular Testing and ALK-Positive NSCLC References
Molecular testing is essential for identifying patients whose cancer may respond to ALK-targeted treatment.
Reference 9: CAP, IASLC, and AMP Molecular Testing Guidelines
- Organizations:
- College of American Pathologists (CAP).
- International Association for the Study of Lung Cancer (IASLC).
- Association for Molecular Pathology (AMP).
- Document: Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors.
Relevant information:
- Molecular testing in lung cancer.
- ALK genetic alterations.
- Diagnostic testing methods.
- Selection of patients for targeted therapy.
- The role of molecular biomarkers in treatment decisions.
Relevance to this website:
These guidelines provide professional background for understanding why appropriate molecular testing is important before prescribing an ALK inhibitor.
4. Clinical and Educational Topics Supported by These References
The sources listed above provide information relevant to several subjects discussed throughout the website.
| Website topic | Relevant reference sources |
|---|---|
| What is alectinib? | FDA prescribing information, EMA product information |
| Alectinib therapeutic uses | FDA prescribing information, EMA EPAR |
| How alectinib works | Prescribing information and clinical research |
| ALK-positive NSCLC | Molecular testing guidelines |
| Dosage and administration | FDA and EMA product information |
| Treatment after surgery | ALINA clinical trial |
| Advanced NSCLC treatment | ALEX and J-ALEX clinical trials |
| Central nervous system activity | ALEX clinical trial |
| Side effects and safety | FDA prescribing information and clinical trials |
| Treatment monitoring | FDA prescribing information |
| Long-term outcomes | ALEX final analysis |
| Quality of life | ALINA safety and quality-of-life analysis |
5. Important Distinction Between Alectinib References and Alecnib Product Information
The references on this page primarily concern the active ingredient alectinib and the established reference product Alecensa.
They provide scientific and regulatory background for understanding alectinib as a medicine. They do not independently verify Alecnib as a specific commercial product.
The following details require separate product-specific evidence:
- Alecnib’s legal manufacturer.
- Manufacturing location.
- Product registration or authorization.
- Exact dosage form.
- Batch-specific quality information.
- Product authenticity.
- Pharmaceutical equivalence to another alectinib brand.
- Country-specific distribution and availability.
Patients and healthcare professionals should obtain these details from reliable manufacturer documentation, original packaging, and applicable national regulatory records.
6. Medical Literature and Reference Use
Medical references should be interpreted according to their publication date, research design, study population, and clinical context.
Clinical trial results do not guarantee that every patient will experience the same treatment outcomes.
Regulatory documents may also differ between countries. Therefore, the applicable local prescribing information should take priority when determining approved indications, dosage, warnings, and precautions.
The educational content on this website should be reviewed periodically to reflect important changes in prescribing information and clinical evidence.
7. Important Reference Disclaimer
The references listed on this page are provided to identify scientific and regulatory resources relevant to alectinib.
They are not intended to establish that Alecnib has the same regulatory approval, manufacturer, formulation, quality standards, or prescribing instructions as Alecensa.
No clinical trial involving alectinib should be interpreted as direct evidence of the quality, authenticity, or regulatory status of a specific Alecnib package unless that product was independently identified and evaluated in the relevant research.
Always consult the current official prescribing information and a qualified healthcare professional before making decisions about alectinib treatment.